Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
122
Recruiting Now
122
Top Conditions in Phase 2 / Phase 3
Gastric Cancer (2) Pancreatic Ductal Adenocarcinoma (2) Breast Cancer (2) Non-Squamous Non-Small Cell Lung Cancer (2) Primary Central Nervous System Lymphoma (2) Multiple Myeloma (2) HCC (2) Heart Failure (2) Acute Myeloid Leukemia (2) Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (1)
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT06856525 Phase 2, Phase 3
Recruiting
Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology
Condition
Electronic Cigarette Related Lung Damage
Enrollment
80 pts
Location
United States
Sponsor
Y. Michael Shim, MD
NCT07086313 Phase 2, Phase 3
Recruiting
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients Wit...
Condition
Attention-Deficit Hyperactivity Disorder(ADHD)
Enrollment
315 pts
Location
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd
NCT02657785 Phase 2, Phase 3
Recruiting
Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
Condition
Primary Central Nervous System Lymphoma
Enrollment
100 pts
Location
China
Sponsor
Navy General Hospital, Beijing
NCT04513639 Phase 2, Phase 3
Recruiting
The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
Condition
Multiple Myeloma
Enrollment
176 pts
Location
Norway
Sponsor
Oslo University Hospital
NCT05855369 Phase 2, Phase 3
Recruiting
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Lo...
Condition
Smell Dysfunction
Enrollment
145 pts
Location
United States
Sponsor
Medical University of South Ca
NCT06537154 Phase 2, Phase 3
Recruiting
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillanc...
Condition
Muscle-Invasive Bladder Carcinoma
Enrollment
688 pts
Location
Canada
Sponsor
Peter Black
NCT07472153 Phase 2, Phase 3
Recruiting
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check ...
Condition
Metastatic Cervical Cancer
Enrollment
120 pts
Location
Belarus
Sponsor
N.N. Alexandrov National Cance
NCT07018661 Phase 2, Phase 3
Recruiting
[18F]F-FAPI PET/CT and Laparoscopy in Staging Advanced Gastric Cancer
Condition
Locally Advanced Gastric Adenocarcinoma
Enrollment
250 pts
Location
Netherlands
Sponsor
Leiden University Medical Cent
NCT06702241 Phase 2, Phase 3
Recruiting
Newborn Jaundice - An Investigation of Different Approaches to Light Therapy
Condition
Neonatal Hyperbilirubinemia
Enrollment
116 pts
Location
Denmark
Sponsor
Regionshospital Nordjylland
NCT06109272 Phase 2, Phase 3
Recruiting
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Li...
Condition
Hepatocellular Carcinoma
Enrollment
660 pts
Location
United States, France, Italy
Sponsor
AbbVie
NCT07496567 Phase 2, Phase 3
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-...
Condition
Macular Degeneration
Enrollment
960 pts
Location
United States
Sponsor
EyeBiotech Ltd.
NCT05254171 Phase 2, Phase 3
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Ca...
Condition
Pancreatic Cancer Metastatic
Enrollment
600 pts
Location
United States, Australia, Austria
Sponsor
Panbela Therapeutics, Inc.
NCT03818334 Phase 2, Phase 3
Recruiting
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplant...
Condition
Bone Marrow Transplant Complications
Enrollment
50 pts
Location
Brazil
Sponsor
Hospital Israelita Albert Eins
NCT06085716 Phase 2, Phase 3
Recruiting
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cance...
Condition
Metastatic Cancers
Enrollment
240 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05267821 Phase 2, Phase 3
Recruiting
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Condition
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Enrollment
500 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT03143374 Phase 2, Phase 3
Recruiting
PET Tau - Neurodegenerative Disease Imaging
Condition
Neurodegenerative Disease
Enrollment
300 pts
Location
United States
Sponsor
University of Pennsylvania
NCT04351347 Phase 2, Phase 3
Recruiting
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
Condition
COVID
Enrollment
300 pts
Location
Egypt
Sponsor
Tanta University
NCT05398484 Phase 2, Phase 3
Recruiting
Psilocybin Therapy in Advanced Cancer
Condition
Advanced Cancer
Enrollment
200 pts
Location
United States
Sponsor
NYU Langone Health
NCT05664789 Phase 2, Phase 3
Recruiting
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
Condition
Autism Spectrum Disorder
Enrollment
144 pts
Location
United States
Sponsor
Stanford University
NCT07194850 Phase 2, Phase 3
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years o...
Condition
Immune Thrombocytopenia (ITP)
Enrollment
24 pts
Location
Germany, Italy, Poland
Sponsor
argenx
NCT07658534 Phase 2, Phase 3
Recruiting
A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Viru...
Condition
Respiratory Syncytial Virus Infections
Enrollment
290 pts
Location
China
Sponsor
Shanghai Ark Biopharmaceutical
NCT04310930 Phase 2, Phase 3
Recruiting
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Condition
Pulmonary Disease Due to Mycobacteria (Diagnosis)
Enrollment
300 pts
Location
Australia, Denmark, Israel
Sponsor
The University of Queensland
NCT06138028 Phase 2, Phase 3
Recruiting
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cance...
Condition
Metastatic Esophageal Squamous Cell Carcinoma
Enrollment
90 pts
Location
China
Sponsor
Qingdao Central Hospital
NCT06345339 Phase 2, Phase 3
Recruiting
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Syn...
Condition
Hypothyroidism
Enrollment
2,800 pts
Location
United States, Puerto Rico
Sponsor
AbbVie
NCT06456528 Phase 2, Phase 3
Recruiting
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Condition
Cancer Treatment-Induced Thrombocytopenia
Enrollment
235 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology